Introduction：Basic information about CAS 80681-45-4|Prim-O-glucosylcimifugin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Prim-O-glucosylcimifugin |
|---|
| CAS Number | 80681-45-4 | Molecular Weight | 468.451 |
|---|
| Density | 1.5±0.1 g/cm3 | Boiling Point | 736.9±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C22H28O11 | Melting Point | 120 °C |
|---|
| MSDS | / | Flash Point | 255.0±26.4 °C |
|---|
Names
| Name | (2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrofuro[3,2-g]chromen-5-one |
|---|
| Synonym | More Synonyms |
|---|
Prim-O-glucosylcimifugin BiologicalActivity
| Description | Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling. |
|---|
| Related Catalog | Signaling Pathways >>Immunology/Inflammation >>NO SynthaseResearch Areas >>Inflammation/ImmunologyNatural Products >>Others |
|---|
| Target | iNOS COX-2 |
|---|
| In Vitro | Prim-O-glucosylcimifugin (POG) is the highest content chromone and one of the major active constituents in Radix Saposhnikoviae (RS). Prim-O-glucosylcimifugin exerts anti-inflammatory effects in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 expression by inhibiting JAK2/STAT3 signaling. The cytotoxicity of Prim-O-glucosylcimifugin is measured to LPS-activated Raw 264.7 macrophages. Raw 264.7 macrophages are treated with LPS (1 μg/mL) and increasing concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h and cell viability is evaluated by CCK-8 assay. Cell viability is not significantly affected after 24 h and exposure to 15-100 μg/mL Prim-O-glucosylcimifugin as compared with DMSO-treated cells (control). To investigate the anti-inflammatory effect of Prim-O-glucosylcimifugin, whether Prim-O-glucosylcimifugin can affect NO synthesis is examined in LPS-activated RAW 264.7 cells. Macrophages are treated with LPS (1 μg/mL) and various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h. No concentrations are measured in the culture supernatants by Griess reaction. The concentrations of NO in the culture supernatants are markedly increased in response to LPS exposure, and Prim-O-glucosylcimifugin significantly inhibits LPS-induced NO production in a concentration-dependent manner[1]. |
|---|
| In Vivo | Bronchoalveolar lavage fluid (BALF) is collected at 7 h after lipopolysaccharide (LPS) administration and thecytokine levels in BALF are measured by ELISA. The levels of TNF-α, IL-1β and IL-6 in BALF are increased dramatically compared with control group. However, pretreatment with Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg) significantly down-regulates the levels of TNF-α, IL-1β and IL-6 in a dose-dependent manner (P<0.05, P<0.01)[1]. |
|---|
| Cell Assay | Cell Counting Kit (CCK-8) is used to determine the cytotoxic concentrations of Prim-O-glucosylcimifugin. In brief, the Raw 264.7 cells are plated at a density of 1×104 cells per well in a 96-well and incubated overnight. Cells are then stimulated with 1 μg/mL LPS and treated with various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL; MedChem Express, Princeton, NJ, USA) or DMSO. After incubation at 37°C for 24 h, CCK-8 solution is added to each well and incubated for another 1 h. The absorbance is measured at 450 nm using a microplate reader[1]. |
|---|
| Animal Admin | Mice[1] BALB/c male mice, 8 weeks old and weighing approximately 18 to 20 g, are used. The mice are randomly divided into five groups: Control group; LPS group; LPS+Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg bodyweight). Prime-O-glucosylcimifugin is given intraperitoneally. One hour later, LPS group and LPS+Prime-O-glucosylcimifugin group mice are given 50 μL LPS intranasally (i.n) (200 mg/L) to induce acute lung injury. Control mice are given 50 μL PBS intranasally (i.n) without LPS[1]. |
|---|
| References | [1]. Zhou J, et al. Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages. Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384. [2]. Chen N, et al. Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2013 Jun;16(2):139-47. |
|---|
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|
| Boiling Point | 736.9±60.0 °C at 760 mmHg |
|---|
| Melting Point | 120 °C |
|---|
| Molecular Formula | C22H28O11 |
|---|
| Molecular Weight | 468.451 |
|---|
| Flash Point | 255.0±26.4 °C |
|---|
| Exact Mass | 468.163147 |
|---|
| PSA | 168.28000 |
|---|
| LogP | -1.35 |
|---|
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
|---|
| Index of Refraction | 1.648 |
|---|
| InChIKey | XIUVHOSBSDYXRG-UVTAEQIVSA-N |
|---|
| SMILES | COc1c2c(cc3oc(COC4OC(CO)C(O)C(O)C4O)cc(=O)c13)OC(C(C)(C)O)C2 |
|---|
Safety Information
| Safety Phrases | 24/25 |
|---|
| HS Code | 29389090 |
|---|
Synonyms
| 5H-Furo[3,2-g][1]benzopyran-5-one, 7-[(β-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (2S)- |
| HMS2196A10 |
| [(2S)-2-(2-Hydroxypropan-2-yl)-4-methoxy-5-oxo-2,3-dihydro-5H-furo[3,2-g]chromen-7-yl]methyl β-D-glucopyranoside |
| N1606 |
| [(2S)-2-(2-Hydroxy-2-propanyl)-4-methoxy-5-oxo-2,3-dihydro-5H-furo[3,2-g]chromen-7-yl]methyl β-D-glucopyranoside |
| Prim-O-glucosylcimifugin |
